Dr Richard Kevin

Telephone +61 2 9114 4238

Website ResearchGate
Twitter
Google Scholar

Biographical details

Richard Kevin is an analytical chemist and behavioural pharmacologist with the Lambert Initiative for Cannabinoid Therapeutics, at the Brain and Mind Centre, The University of Sydney. His research investigates the science of cannabis and the cannabinoids,with a focus on their chemistry, pharmacology, and the discovery of new cannabinoid-based therapeutics.

Richard also studies new psychoactive substances (NPS) ("designer drugs"), and works to characterise their pharmacological properties and to develop methods for their detection. He works closely with researchers at UCSF, RTI International, Macquarie University, and Otago University to rapidly evaluate novel psychoactives as they emerge in the community.

Richard regularly reviews for several analytical and behavioural science journals, and sits on the editorial advisory board for Forensic Toxicology.

Awards and honours

Top Postdoctoral Presentation, The International Cannabinoid Research Society Annual Symposium (2017)

School of Psychology Publication Prize, The Univerisity of Sydney (2017)

Royston George Booker Scholarship, The University of Sydney (2016)

Sydney University Graduates Union of North America Alumni Scholarship (2016)

In the media

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Allsop, D., Kevin, R., Arnold, J. (2016). Cannabis: The Pharmacokinetics and Pharmacodynamics of Recreational and Medicinal Cannabis. In K. Wolff, J. White & S. Karch (Eds.), The SAGE Handbook of Drug & Alcohol Studies Volume 2, (pp. 1-19). London: Sage Publications Ltd. [More Information]

Journals

  • Arkell, T., Lintzeris, N., Kevin, R., Ramaekers, J., Vandrey, R., Irwin, C., Haber, P., McGregor, I. (2019). Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition. Psychopharmacology, 236(9), 2713-2724. [More Information]
  • Kevin, R., Anderson, L., McGregor, I., Boyd, R., Manning, J., Glass, M., Connor, M., Banister, S. (2019). CUMYL-4CN-BINACA is an efficacious and potent pro-convulsant synthetic cannabinoid receptor agonist. Frontiers in Pharmacology, 10(595), 1-9. [More Information]
  • Bedoya-Perez, M., Smith, K., Kevin, R., Luo, J., Crowther, M., McGregor, I. (2019). Parameters That Affect Fear Responses in Rodents and How to Use Them for Management. Frontiers in Ecology and Evolution, 7, 136. [More Information]
  • Banister, S., Adams, A., Kevin, R., MacDonald, C., Glass, M., Boyd, R., Connor, M., McGregor, I., Havel, C., Bright, S., et al (2019). Synthesis and pharmacology of new psychoactive substance 5F-CUMYL-P7AICA, a scaffold- hopping analog of synthetic cannabinoid receptor agonists 5F-CUMYL-PICA and 5F-CUMYL-PINACA. Drug Testing and Analysis, 11(2), 279-291. [More Information]
  • Banister, S., Kevin, R., Martin, L., Adams, A., MacDonald, C., Manning, J., Boyd, R., Cunningham, M., Stevens, M., McGregor, I., et al (2019). The chemistry and pharmacology of putative synthetic cannabinoid receptor agonist (SCRA) new psychoactive substances (NPS) 5F-PY-PICA, 5F-PY-PINACA, and their analogs. Drug Testing and Analysis, 11(7), 976-989. [More Information]
  • Kevin, R., Kovach, A., Lefever, T., Gamage, T., Wiley, J., McGregor, I., Thomas, B. (2019). Toxic by design? Formation of thermal degradants and cyanide from carboxamide-type synthetic cannabinoids CUMYL-PICA, 5F-CUMYL-PICA, AMB-FUBINACA, MDMB-FUBINACA, NNEI, and MN-18 during exposure to high temperatures. Forensic Toxicology, 37(1), 17-26. [More Information]
  • Suraev, A., Lintzeris, N., Stuart, J., Kevin, R., Blackburn, R., Richards, E., Arnold, J., Ireland, C., Todd, L., Allsop, D., McGregor, I. (2018). Author Correction: Composition and Use of Cannabis Extracts for Childhood Epilepsy in the Australian Community. Scientific Reports, 8(1), 1-1. [More Information]
  • Suraev, A., Lintzeris, N., Stuart, J., Kevin, R., Blackburn, R., Richards, E., Arnold, J., Ireland, C., Todd, L., Allsop, D., McGregor, I. (2018). Composition and Use of Cannabis Extracts for Childhood Epilepsy in the Australian Community. Scientific Reports, 8(1), 28127. [More Information]
  • Kevin, R., Lefever, T., Snyder, R., Patel, P., Gamage, T., Fennell, T., Wiley, J., McGregor, I., Thomas, B. (2018). Kinetic and metabolic profiles of synthetic cannabinoids NNEI and MN-18. Drug Testing and Analysis, 10(1), 137-147. [More Information]
  • Gamage, T., Farquhar, C., Lefever, T., Marusich, J., Kevin, R., McGregor, I., Wiley, J., Thomas, B. (2018). Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA. Journal of Pharmacology and Experimental Therapeutics, 365(2), 437-446. [More Information]
  • Banister, S., Olson, A., Winchester, M., Stuart, J., Edington, A., Kevin, R., Longworth, M., Herrera, M., Connor, M., McGregor, I., Kassiou, M., et al (2018). The chemistry and pharmacology of synthetic cannabinoid SDB-006 and its regioisomeric fluorinated and methoxylated analogs. Drug Testing and Analysis, 10(7), 1099-1109. [More Information]
  • Kevin, R., Wood, K., Stuart, J., Mitchell, A., Moir, M., Banister, S., Kassiou, M., McGregor, I. (2017). Acute and residual effects in adolescent rats resulting rrom exposure to the novel synthetic cannabinoids AB-PINACA and AB-FUBINACA. Journal of Psychopharmacology, 31(6), 757-769. [More Information]
  • Kevin, R., Lefever, T., Snyder, R., Patel, P., Fennell, T., Wiley, J., McGregor, I., Thomas, B. (2017). In vitro and in vivo pharmacokinetics and metabolism of synthetic cannabinoids CUMYL-PICA and 5F-CUMYL-PICA. Forensic Toxicology, 35(2), 333-347. [More Information]
  • Longworth, M., Banister, S., Boyd, R., Kevin, R., Connor, M., McGregor, I., Kassiou, M. (2017). Pharmacology of cumyl-carboxamide synthetic cannabinoid new psychoactive substances (NPS) CUMYL-BICA, CUMYL-PICA, CUMYL-5F-PICA, CUMYL-5F-PINACA, and their analogues. ACS Chemical Neuroscience, 8(10), 2159-2167. [More Information]
  • Thomas, B., Lefever, T., Cortes, R., Grabenauer, M., Kovach, A., Cox, A., Patel, P., Pollard, G., Marusich, J., Kevin, R., et al (2017). Thermolytic degradation of synthetic cannabinoids: Chemical exposures and pharmacological consequences. Journal of Pharmacology and Experimental Therapeutics, 361(1), 162-171. [More Information]
  • Kevin, R., Allsop, D., Lintzeris, N., Dunlop, A., Booth, J., McGregor, I. (2017). Urinary cannabinoid levels during nabiximols (Sativex)-medicated inpatient cannabis withdrawal. Forensic Toxicology, 35(1), 33-44. [More Information]
  • Lefever, T., Marusich, J., Thomas, B., Barrus, D., Peiper, N., Kevin, R., Wiley, J. (2017). Vaping Synthetic Cannabinoids: A Novel Preclinical Model of E-Cigarette Use in Mice. Substance Abuse: Research and Treatment, 11, 1-8. [More Information]
  • Banister, S., Longworth, M., Kevin, R., Sachdev, S., Santiago, M., Stuart, J., Mack, J., Glass, M., McGregor, I., Connor, M., Kassiou, M. (2016). Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues. ACS Chemical Neuroscience, 7(9), 1241-1254. [More Information]
  • Banister, S., Stuart, J., Kevin, R., Edington, A., Longworth, M., Wilkinson, S., Beinat, C., Buchanan, A., Hibbs, D., Glass, M., McGregor, I., Kassiou, M., et al (2015). Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. ACS Chemical Neuroscience, 6(8), 1445-1458. [More Information]
  • Banister, S., Moir, M., Stuart, J., Kevin, R., Wood, K., Longworth, M., Wilkinson, S., Beinat, C., Buchanan, A., Glass, M., McGregor, I., Kassiou, M., et al (2015). Pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. ACS Chemical Neuroscience, 6(9), 1546-1559. [More Information]
  • Banister, S., Stuart, J., Conroy, T., Longworth, M., Manohar, M., Beinat, C., Wilkinson, S., Kevin, R., Hibbs, D., Glass, M., McGregor, I., Kassiou, M., et al (2015). Structure-activity relationships of synthetic cannabinoid designer drug RCS-4 and its regioisomers and C4 homologues. Forensic Toxicology, 33(2), 355-366. [More Information]
  • Ramos, L., Hicks, C., Kevin, R., Caminer, A., Narlawar, R., Kassiou, M., McGregor, I. (2013). Acute Prosocial Effects of Oxytocin and Vasopressin When Given Alone or in Combination with 3,4-Methylenedioxymethamphetamine in Rats: Involvement of the VI(A) Receptor. Neuropsychopharmacology, 38(11), 2249-2259. [More Information]
  • Bowen, M., Kevin, R., May, M., Staples, L., Hunt, G., McGregor, I. (2013). Defensive Aggregation (Huddling) in Rattus Norvegicus toward Predator Odor: Individual Differences, Social Buffering Effects and Neural Correlates. PloS One, 8(7), 1-15. [More Information]

2019

  • Arkell, T., Lintzeris, N., Kevin, R., Ramaekers, J., Vandrey, R., Irwin, C., Haber, P., McGregor, I. (2019). Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition. Psychopharmacology, 236(9), 2713-2724. [More Information]
  • Kevin, R., Anderson, L., McGregor, I., Boyd, R., Manning, J., Glass, M., Connor, M., Banister, S. (2019). CUMYL-4CN-BINACA is an efficacious and potent pro-convulsant synthetic cannabinoid receptor agonist. Frontiers in Pharmacology, 10(595), 1-9. [More Information]
  • Bedoya-Perez, M., Smith, K., Kevin, R., Luo, J., Crowther, M., McGregor, I. (2019). Parameters That Affect Fear Responses in Rodents and How to Use Them for Management. Frontiers in Ecology and Evolution, 7, 136. [More Information]
  • Banister, S., Adams, A., Kevin, R., MacDonald, C., Glass, M., Boyd, R., Connor, M., McGregor, I., Havel, C., Bright, S., et al (2019). Synthesis and pharmacology of new psychoactive substance 5F-CUMYL-P7AICA, a scaffold- hopping analog of synthetic cannabinoid receptor agonists 5F-CUMYL-PICA and 5F-CUMYL-PINACA. Drug Testing and Analysis, 11(2), 279-291. [More Information]
  • Banister, S., Kevin, R., Martin, L., Adams, A., MacDonald, C., Manning, J., Boyd, R., Cunningham, M., Stevens, M., McGregor, I., et al (2019). The chemistry and pharmacology of putative synthetic cannabinoid receptor agonist (SCRA) new psychoactive substances (NPS) 5F-PY-PICA, 5F-PY-PINACA, and their analogs. Drug Testing and Analysis, 11(7), 976-989. [More Information]
  • Kevin, R., Kovach, A., Lefever, T., Gamage, T., Wiley, J., McGregor, I., Thomas, B. (2019). Toxic by design? Formation of thermal degradants and cyanide from carboxamide-type synthetic cannabinoids CUMYL-PICA, 5F-CUMYL-PICA, AMB-FUBINACA, MDMB-FUBINACA, NNEI, and MN-18 during exposure to high temperatures. Forensic Toxicology, 37(1), 17-26. [More Information]

2018

  • Suraev, A., Lintzeris, N., Stuart, J., Kevin, R., Blackburn, R., Richards, E., Arnold, J., Ireland, C., Todd, L., Allsop, D., McGregor, I. (2018). Author Correction: Composition and Use of Cannabis Extracts for Childhood Epilepsy in the Australian Community. Scientific Reports, 8(1), 1-1. [More Information]
  • Suraev, A., Lintzeris, N., Stuart, J., Kevin, R., Blackburn, R., Richards, E., Arnold, J., Ireland, C., Todd, L., Allsop, D., McGregor, I. (2018). Composition and Use of Cannabis Extracts for Childhood Epilepsy in the Australian Community. Scientific Reports, 8(1), 28127. [More Information]
  • Kevin, R., Lefever, T., Snyder, R., Patel, P., Gamage, T., Fennell, T., Wiley, J., McGregor, I., Thomas, B. (2018). Kinetic and metabolic profiles of synthetic cannabinoids NNEI and MN-18. Drug Testing and Analysis, 10(1), 137-147. [More Information]
  • Gamage, T., Farquhar, C., Lefever, T., Marusich, J., Kevin, R., McGregor, I., Wiley, J., Thomas, B. (2018). Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA. Journal of Pharmacology and Experimental Therapeutics, 365(2), 437-446. [More Information]
  • Banister, S., Olson, A., Winchester, M., Stuart, J., Edington, A., Kevin, R., Longworth, M., Herrera, M., Connor, M., McGregor, I., Kassiou, M., et al (2018). The chemistry and pharmacology of synthetic cannabinoid SDB-006 and its regioisomeric fluorinated and methoxylated analogs. Drug Testing and Analysis, 10(7), 1099-1109. [More Information]

2017

  • Kevin, R., Wood, K., Stuart, J., Mitchell, A., Moir, M., Banister, S., Kassiou, M., McGregor, I. (2017). Acute and residual effects in adolescent rats resulting rrom exposure to the novel synthetic cannabinoids AB-PINACA and AB-FUBINACA. Journal of Psychopharmacology, 31(6), 757-769. [More Information]
  • Kevin, R., Lefever, T., Snyder, R., Patel, P., Fennell, T., Wiley, J., McGregor, I., Thomas, B. (2017). In vitro and in vivo pharmacokinetics and metabolism of synthetic cannabinoids CUMYL-PICA and 5F-CUMYL-PICA. Forensic Toxicology, 35(2), 333-347. [More Information]
  • Longworth, M., Banister, S., Boyd, R., Kevin, R., Connor, M., McGregor, I., Kassiou, M. (2017). Pharmacology of cumyl-carboxamide synthetic cannabinoid new psychoactive substances (NPS) CUMYL-BICA, CUMYL-PICA, CUMYL-5F-PICA, CUMYL-5F-PINACA, and their analogues. ACS Chemical Neuroscience, 8(10), 2159-2167. [More Information]
  • Thomas, B., Lefever, T., Cortes, R., Grabenauer, M., Kovach, A., Cox, A., Patel, P., Pollard, G., Marusich, J., Kevin, R., et al (2017). Thermolytic degradation of synthetic cannabinoids: Chemical exposures and pharmacological consequences. Journal of Pharmacology and Experimental Therapeutics, 361(1), 162-171. [More Information]
  • Kevin, R., Allsop, D., Lintzeris, N., Dunlop, A., Booth, J., McGregor, I. (2017). Urinary cannabinoid levels during nabiximols (Sativex)-medicated inpatient cannabis withdrawal. Forensic Toxicology, 35(1), 33-44. [More Information]
  • Lefever, T., Marusich, J., Thomas, B., Barrus, D., Peiper, N., Kevin, R., Wiley, J. (2017). Vaping Synthetic Cannabinoids: A Novel Preclinical Model of E-Cigarette Use in Mice. Substance Abuse: Research and Treatment, 11, 1-8. [More Information]

2016

  • Allsop, D., Kevin, R., Arnold, J. (2016). Cannabis: The Pharmacokinetics and Pharmacodynamics of Recreational and Medicinal Cannabis. In K. Wolff, J. White & S. Karch (Eds.), The SAGE Handbook of Drug & Alcohol Studies Volume 2, (pp. 1-19). London: Sage Publications Ltd. [More Information]
  • Banister, S., Longworth, M., Kevin, R., Sachdev, S., Santiago, M., Stuart, J., Mack, J., Glass, M., McGregor, I., Connor, M., Kassiou, M. (2016). Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues. ACS Chemical Neuroscience, 7(9), 1241-1254. [More Information]

2015

  • Banister, S., Stuart, J., Kevin, R., Edington, A., Longworth, M., Wilkinson, S., Beinat, C., Buchanan, A., Hibbs, D., Glass, M., McGregor, I., Kassiou, M., et al (2015). Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. ACS Chemical Neuroscience, 6(8), 1445-1458. [More Information]
  • Banister, S., Moir, M., Stuart, J., Kevin, R., Wood, K., Longworth, M., Wilkinson, S., Beinat, C., Buchanan, A., Glass, M., McGregor, I., Kassiou, M., et al (2015). Pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. ACS Chemical Neuroscience, 6(9), 1546-1559. [More Information]
  • Banister, S., Stuart, J., Conroy, T., Longworth, M., Manohar, M., Beinat, C., Wilkinson, S., Kevin, R., Hibbs, D., Glass, M., McGregor, I., Kassiou, M., et al (2015). Structure-activity relationships of synthetic cannabinoid designer drug RCS-4 and its regioisomers and C4 homologues. Forensic Toxicology, 33(2), 355-366. [More Information]

2013

  • Ramos, L., Hicks, C., Kevin, R., Caminer, A., Narlawar, R., Kassiou, M., McGregor, I. (2013). Acute Prosocial Effects of Oxytocin and Vasopressin When Given Alone or in Combination with 3,4-Methylenedioxymethamphetamine in Rats: Involvement of the VI(A) Receptor. Neuropsychopharmacology, 38(11), 2249-2259. [More Information]
  • Bowen, M., Kevin, R., May, M., Staples, L., Hunt, G., McGregor, I. (2013). Defensive Aggregation (Huddling) in Rattus Norvegicus toward Predator Odor: Individual Differences, Social Buffering Effects and Neural Correlates. PloS One, 8(7), 1-15. [More Information]

To update your profile click here. For support on your academic profile contact .